BillionToOne Is Solving One of Biotech’s Hardest Problems

Illumina, Inc.

Illumina is a leading NGS platform and consumables provider, and cfDNA diagnostic volume growth is generally supportive. However, the source does not confirm BillionToOne uses Illumina systems or that incremental volumes are material.

TMO is Thermo Fisher Scientific Inc, a Healthcare equity in the Diagnostics & Research industry.

Thermo Fisher could benefit broadly from molecular diagnostics tools, reagents, and lab infrastructure demand, but the read-through is highly indirect.

YC Paper Club recap highlighting emerging AI research directions: scaling laws applied to protein biology (ESM), AlphaZero-style self-play for LLMs, streaming RAG for real-time voice agents, formal verification with Lean, and “agentic” programming workflows. This is directional/strategic (themes) rather than a specific catalyst with near-term dates.

Fireside chat describes Meesho’s rapid scale in India mass-market e-commerce/social commerce (Android #1 shopping app; ~1M sellers; claimed very high order volume), key pivots (WhatsApp-group distribution; business-model changes after Jio disrupted earlier assumptions), and forward-looking theme around voice/AI to expand addressable buyers. Meesho is private; implications are second-order for listed India e-commerce competitors, logistics, payments, telco, and digital ads/cloud.

The Most AI-Pilled CEO We Know Brex co-founder and CEO Pedro Franceschi believes most people still underestimate how much AI will change the way companies are built. AI isn't just another tool, it's a new foundation for building products, teams, and companies. In this episode of Lightcone, Pedro shares why he thinks we're only months into a platform shift as significant as the invention of electricity, how AI has changed the way he works, and why every founder should be "token maxing" to understand the limits of the technology firsthand. He explains why the CEO needs to be the chief AI officer, how Brex is rebuilding itself around AI, and why founders should rethink what's possible when intelligence is available on demand. Apply to Y Combinator: https://www.ycombinator.com/apply Work at a startup: https://www.ycombinator.com/jobs Chapters: 01:13 – How Pedro Became AI-Pilled 04:08 – The Electricity Analogy 05:21 – Free the Claw 06:56 – Making AI Safe for Enterprise 10:57 – Why Most Companies Are Behind 13:09 – AI Teammates, Not Chatbots 14:22 – The Case for Tokenmaxxing 18:24 – The Company of One 20:54 – The One Thing AI Can't Replace 28:06 – Building Customer World Models 32:58 – R

Transcript-style startup/YC commentary about focusing on building working software vs demos; mentions revenue run-rate, GTM, opening an SF office, and doing RL/agents/JSON output. Contains no specific public-company names or tradable catalysts.

Transcript-like, low-signal narrative about startup Legora’s YC experience and rapid ARR growth; few concrete market-relevant facts. Only clear public-company reference is SAP.

YC-style interview/video about Conductor CEO describing an AI-assisted coding workflow (agents, MCP, Codex vs Claude, enforcing workflows). It’s product/workflow commentary, not a market-moving datapoint (no financial metrics, partnerships, pricing, or adoption numbers). Actionability is therefore low, but it reinforces the broader thesis that AI coding assistants/agents are becoming standard developer tooling and will continue to drive compute and model usage.

YC-style guidance on building AI services businesses: services + AI can work in regulated, skeptical-buyer markets (e.g., FDA/regulatory consulting, legal services), but economics differ from SaaS (gross margins often ~30% vs 50%+). Warns against “buy a services firm and sprinkle AI” roll-up strategies and against pilots with zero/negative margins; stresses selling outcomes vs seats and human-in-the-loop costs.

Link/title-only entry with no substantive content beyond repeating the title, so no extractable market, product, or ticker-relevant evidence.